Research Study: PACES
Quitting smoking following acute coronary syndrome
Study Sponsor: MHIF
Study Investigator: Michael Miedema, MD
Study Contact: Christine Majeski
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

Quitting smoking following acute coronary syndrome (ACS) can reduce mortality up to 50%. However, depression and smoking are highly co-morbid and depressed mood may interfere with cessation and independently predicts mortality. Thus, a single, integrated treatment for both smoking and depression could be highly effective in reducing post-acute coronary syndrome mortality. Behavioral Activation (BA) is a well established treatment for depression and has recently shown promise as a treatment for smoking cessation. The investigators systematically developed an intervention integrating gold standard smoking cessation counseling with existing BA based mood management techniques for post-ACS smokers; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS). Objective: For this R01 the investigators will evaluate the efficacy of using a single, integrated treatment that targets both depressed mood and smoking (BAT-CS).
Eligibility Criteria:

  • hospital inpatients with an ACS diagnosis documented in medical record within the past 30 days
  • smoked equal or greater than 1 cigarette per day before being hospitalized
  • age of 18-75 years
  • English fluency
  • willing to consider quitting smoking at discharge
  • has a telephone or is willing to use a study issued cell phone
  • willing to consent to all study procedures.

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!